Name: Survodutide
Brand: Lilipeptide
SKU: LILI-survodutide
Price: 420.00 USD
Availability: InStock

Survodutide at a glance

Survodutide is a synthetic, lipidated peptide developed by Boehringer Ingelheim, with discovery origins in a collaboration with Zealand Pharma. Its sequence is engineered so the molecule activates two receptors at once, the glucagon receptor and the GLP-1 receptor, while a fatty-acid side chain extends its time in circulation. It belongs to a growing class of multi-receptor incretin-type peptides and is distinct from GIP-containing agonists such as tirzepatide.

Price and availability

Sold by Lilipeptide and sent from China, this listing is a listing. It is listed at $420.00. As with every order here, the brand is paid only after you confirm delivery.

This listing: Lilipeptide Survodutide

Brand: Lilipeptide
Also sold by: Uther Peptide 10mg $230.00 · HK Peptide 10mg $300.00 · TFC Peptides 10mg $210.00 · Jinlu Peptides 10mg $620.10

Lab testing

There is no public lab report for this listing yet. We can ask the brand for the batch COA before you order. Many buyers also split an independent HPLC test with others who bought the same batch.

Request the batch COA · How group testing works

Bought through escrow: the brand is only paid after you confirm delivery. If the parcel never arrives, or an independent test shows the wrong compound or a significant under-fill, open a claim before releasing payment.

What it is studied for

Two receptor actions are combined in one molecule. GLP-1 receptor signaling is studied for reduced food intake, slower gastric emptying and glucose-dependent insulin release. Glucagon receptor signaling, concentrated in the liver, is examined for increased fatty-acid oxidation, reduced hepatic fat and higher energy expenditure, although on its own it tends to raise blood glucose. The GLP-1 component is thought to offset that glycemic effect. The balance between the two activities is a key design variable, and how much each contributes to observed outcomes is still being characterized.

Research and regulatory status

Phase 2 trials in obesity and in metabolic dysfunction-associated steatohepatitis reported reductions in body weight and liver fat compared with placebo, with gastrointestinal effects as the most common adverse events. Phase 3 programs in obesity and liver disease are under way. Survodutide has no regulatory approval, its long-term safety profile is still being established, and research-grade material has no connection to the sponsor's clinical supply.

Checking the lab data

Mass spectrometry should show the intact mass of the lipidated peptide, confirming that the fatty-acid side chain is present, since a peak at the bare-backbone mass would point to a synthesis problem. HPLC purity should be reported with a chromatogram, as closely related sequence and acylation impurities are common for this class. Peptide content per vial and a white, uniform lyophilized cake are also expected.

This listing has no third-party report on file yet. The lab reports directory and the Survodutide page show which brands do publish testing.

Listing details

Compound: Survodutide
Synonyms: BI 456906
Class: Investigational dual glucagon/GLP-1 receptor agonist
Format: Lyophilized (freeze-dried) powder
Sold by: Lilipeptide
Ships from: China
Lab report: Not yet published

Storage and preparation

Freeze-dried peptide keeps best sealed, cold and dark. Once it has been dissolved, refrigerate it, avoid repeated warming and follow the stability limits in your study protocol.

Buyer questions

Why would a metabolic peptide target the glucagon receptor?

Glucagon is best known for raising blood sugar, but in the liver it also promotes fat breakdown and energy use. Survodutide's design aims to capture those hepatic and energy-expenditure effects while GLP-1 receptor activity counters the glucose rise, which is why liver fat is a major endpoint in its trials.

Who is developing survodutide?

Boehringer Ingelheim leads clinical development, building on discovery work carried out with Zealand Pharma. The company code BI 456906 appears in trial registries and publications, which is useful when searching the literature, since early papers may use the code rather than the generic name.

What if the parcel never arrives?

Open a claim from your order page. The payment is still in escrow at that point, so a claim decided in your favour is refunded to your Escrow Wallet.

Supplied for laboratory research only. Not for human or veterinary use, and not a substitute for any prescription medicine. Nothing on this page is medical advice.